MSD posts a victory and defeat for anti-TL1A in skin condition and rare lung disease

Data ReadoutMixedtulisokibartNeutral

AI Analysis

Summary

MSD reported mixed results for its anti-TL1A drug tulisokibart, achieving a positive outcome in a skin condition indication while discontinuing development in systemic sclerosis-associated interstitial lung disease. The company is continuing to evaluate tulisokibart in six different indications.

Outcome Details

Tulisokibart achieved victory in skin condition indication but was discontinued in SSc-ILD. Drug continues to be evaluated in six different indications.

Importance:6/10

Sentiment:

0.00

anti-TL1AtulisokibartSSc-ILDrare diseasedermatologydiscontinuation

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on August 5, 2026 10:02 AM

Read Original